The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
CocconiG.CarliniP.GamboniA.Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol.2003; 14(8): 1258–1263.
2.
CocconiG.BellaM.ZironiS.Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol.1994; 12(12): 2687–2693.
3.
FeliciA.CarliniP.RuggeriE.M.Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study. Cancer Chemother Pharmacol.2006; 57(1): 59–64.
4.
AllegriniG.FalconeA.Di MarsicoR.5-fluorouracil administered as a 48-hour semi-intermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients. Am J Clin Oncol.2004; 27(1): 101–105.
5.
CascinuS.LabiancaR.AlessandroniP.Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, Epi-doxorubicn, 6S-Leucovorin, glutathione, and filgrastim: a report form the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol.1997; 15(11): 3313–3319.
6.
Di CostanzoF.GasperoniS.ManzioneL.Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst.2008; 100(6): 388–398.
BaschE.PrestrudA.A.HeskethP.J.American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2011. J Clin Oncol.2011; 29: 4189–4198.
KrisM.G.GrallaR.J.ClarkR.A.Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol.1985; 3: 1379–1384.
13.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
14.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
15.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
16.
de WitR.de BoerA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
17.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
18.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
19.
CornelisonT.L.ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
20.
KintzelP.E.Anticancer drug-induced kidney disorders – incidence, prevention and management. Drug Safety.2001; 24(1): 19–38.
SmithT.J.KhatcheressianJ.LymanG.H.2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
25.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
26.
MullinS.BeckwithM.C.TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
27.
MarounJ.A.AnthonyL.B.BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
28.
BensonA.B.AjaniJ.A.CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
29.
AronoffG.R.BennettW.M.BernsJ.S.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
30.
KintzelP.E.DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
KingP.D.PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
33.
FloydJ.MirzaI.SachsPerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol2006; 33: 50–67.
34.
DobbsN.A.TwelvesC.J.GregoryW.CruickshanksC.RichardsM.A.RubensR.D.Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer.2003; 39(5): 580–586.
